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sustained antigen-specific CD4 t cell priming in aged hosts 
(12 months old), whereas tumor-specific CD8 t cell prim-
ing was not fully maintained compared to young reference 
animals (2 months old). thus, Cr appears to maintain 
immunological fitness of the CD4 t cell priming environ-
ment during aging, which is critical for optimal OX40-
mediated responses.
Keywords aging · Caloric restriction · resveratrol ·  
t cell · Immunotherapy
Abbreviations
αOX40  OX40 agonist
aCt  adoptive cell therapy
al  ad libitum
Cr  Caloric restriction
lrD  laboratory rodent diet
OVa  Ovalbumin
PD  Purified diet
tCr  t cell receptor
Introduction
It is well understood that the immune system recognizes 
and eradicates tumor cells. More recently, immune-based 
therapies have been shown to be effective in mediating 
durable responses in cancer patients with advanced disease. 
In fact, several immunotherapies, such as high-dose Il-2, 
Ctla-4 blockade and an autologous dendritic cell-based 
tumor vaccine, have been shown to produce significant 
benefit to a subset of patients. additional cancer immu-
notherapeutic approaches, including the blockade of the 
co-inhibitory molecules PD-1 and adoptive t cell therapy, 
have produced objective clinical responses and in some 
Abstract Immune responses wane during aging, pos-
ing challenges to the potential effectiveness of cancer 
immunotherapies. We previously demonstrated that in the 
context of a promising immunotherapeutic, OX40 agonist 
(αOX40), older animals exhibited impaired anti-tumor 
immune responses and diminished CD4 t cell effector 
differentiation. In this study, we hypothesized that tumor 
immune responses could be maintained during aging 
through caloric restriction (Cr) or dietary supplementation 
with resveratrol (reS), a Cr mimetic. Mice were placed 
on either a calorically restricted diet or a reS-formulated 
diet starting between 4 and 6 months of age and contin-
ued until mice reached 12 months of age. tumor immune 
responses were assessed after challenging with either 
sarcoma or breast tumor cells followed by αOX40 treat-
ment. Our results show that Cr, but not reS, maintained 
OX40-mediated anti-tumor immunity. In addition, Cr fully 
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cases produced complete responders in clinical trials [1, 
2]. However, clinical success of established and develop-
ing immunotherapies could ultimately be dependent on the 
effect of aging on immunity, as most cancer patients are 
elderly.
age-related changes occur in both innate and adap-
tive immunity to induce a state of immune deficiency that 
can have an impact on tumor immune responses. It has 
been documented that aging compromises t cell function, 
including the reduction in circulating naïve t cells, impair-
ment of proliferation, and a decrease in Il-2 production 
[3–5]. Innate cells, such as macrophages, neutrophils and 
natural killer cells, can undergo age-mediated decreases 
in function [6]. Dendritic cells (DCs), which are critical 
for the priming of adaptive immune responses, from aged 
animals have been shown to be dysfunctional and are 
reduced in number compared with younger animals [7]. 
the immunological decline associated with aging coincides 
with an increased incidence of tumors in older individuals 
(>65 years old) [8, 9]. although a direct link between age-
impaired immune function and tumor outgrowth has not 
been fully established, tumor immune responses induced 
by vaccines or other immune-based therapies have been 
shown to be deficient in older animals. For example, vac-
cines against breast tumors were significantly less effective 
in older animals [10]. In addition, we have published stud-
ies that described a dramatic age-related decrease in anti-
tumor responses mediated by a promising immunotherapy, 
an OX40 agonist (αOX40) that stimulates the co-stimu-
latory tnF receptor CD134 [11, 12]. Our results suggest 
that a significant decrease in immune function within aged 
tumor-bearing hosts can result in diminished tumor rejec-
tion mediated by an immunotherapy.
Strategies to rejuvenate or maintain anti-tumor immunity 
during aging could improve immunotherapeutic outcomes 
in elderly cancer patients. at this time, caloric restriction 
(Cr) is the most reliable approach to maintain immune 
function during aging. Cr is a substantial reduction in 
caloric intake (30–60 % below ad libitum levels), resulting 
in animals that have fewer and less severe immunological 
deficiencies at advanced ages compared to ad libitum con-
trols [13]. Cr can maintain immune cell function, as seen 
in readouts such as t cell proliferative capacity and Il-2 
production. these cellular changes may account for the sig-
nificant increase in protection against influenza infection 
observed in aged Cr mice [14–16]. In addition to rodents, 
Cr studies with non-human primates also revealed simi-
lar immunological effects, suggesting that humans would 
likely respond favorably to Cr [17].
Maintaining Cr at levels shown to be beneficial is 
extremely difficult lending interest in compounds able to 
recapitulate the effects of Cr. One compound of particular 
interest is the plant phytoalexin resveratrol (reS), which 
has received significant attention as a multi-targeted anti-
aging agent [18]. this compound has been shown to medi-
ate similar physiological, biological, and molecular effects 
of Cr in models ranging from C. elegans to more complex 
non-human primate models [19, 20]. reS can delay the 
onset of a number of diseases though activation of multi-
ple pathways, specifically the naD+/SIrt pathway, and 
increase mitochondrial function [21]. In addition, reS has 
been shown to be an effective activator of SIrt1, but the 
exact mechanism of SIrt1 activation has not been fully elu-
cidated [19]. Despite these promising features, pharmacoki-
netic studies have demonstrated that reS is readily metabo-
lized, prompting its low bioavailability [19]. It is currently 
unknown whether reS or its metabolites are able to accu-
mulate at high enough concentrations in the tissues to be 
effective in vivo. In addition, it is unclear if reS does in fact 
act directly through SIrt proteins or through other targets, 
and whether the results of numerous in vitro studies demon-
strating protective effects can be recapitulated in vivo.
In the studies presented here, we sought to determine 
whether tumor immune responses mediated by an immuno-
therapy could be maintained during aging by dietary inter-
ventions, Cr and/or reS supplementation. Mice were sub-
jected to Cr or reS supplementation starting at ages when 
the immune response was observed to be highly responsive 
and continued until the mice reached 12 months of age, an 
age when immune responses were shown to be significantly 
diminished [11]. these mice were then challenged with 
either one of two different tumors that were demonstrated 
to be responsive to αOX40-mediated tumor immunity in 
young mice, but were unresponsive in 12-month-old as well 
as elderly 20-month-old mice. additional mice were also 
immunized with a protein antigen (ovalbumin) in the con-
text of αOX40 treatment. It was observed that Cr increased 
OX40-mediated anti-tumor immunity in both 12-month-old 
and 18–24-month-old mice compared with age-matched ad 
libitum controls. In contrast, reS supplementation failed to 
have a significant effect on tumor immunity in aged mice. 
analysis of the t cell component of the immune response 
in the mice following dietary intervention suggested that 
OX40-enhanced CD4 t cell activation was maintained in 
aged Cr mice compared to controls. Interestingly, CD8 t 
cell responses were largely unaffected. these findings dem-
onstrate Cr can maintain critical immune responses fol-
lowing treatment with a cancer immunotherapeutic.
Materials and methods
Mice and diets
Six-week-old female Balb/c and C57Bl/6 mice were pur-
chased from Harlan laboratory and used at 8 weeks of 
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age. For the aged mice, 9–10-month-old mice were pur-
chased from Harlan and used at about 12 months of age, 
and 12-, 18-, and 24-month-old ad libitum mice from the 
national Institute on aging (nIa). Calorically restricted 
female C57Bl/6 mice (mean age = 12, 18 and 24 months) 
were purchased from the nIa. DO11.10, OtII, and OtI 
mice were bred and housed until reaching a mean age of 
about 2 months of age. Six-month-old female C57Bl/6 and 
Balb/c mice were fed either a common laboratory rodent 
diet (lrD) (nIH31, Harlan, In; or labDiet5001, Pharma-
Serv, Ma), a purified diet (PD) (aIn93M, Harlan/teklad, 
WI), or a reS supplemented diet (aIn93M/100 ppm reS, 
Harlan/teklad, WI). reS and pterostilbene were purchased 
from Cayman Chemical (ann arbor, MI) and formulated 
by Harlan/teklad (WI). the formulated diets were vacu-
umed, packed, and stored at 4 °C (up to 12 months). the 
aIn93M is formulated for the maintenance of rodents [22] 
and is comprised of less protein (12.4 vs 23.9 %) and fat 
(4.1 vs 5.7 %) compared the lrD, labDiet5001. Once 
mice on formulated diets reached 12 months of age, they 
were placed on the PD for 7–10 days prior to experimen-
tation. all the animals had free access to water and their 
experimental food throughout the experiment. all mice 
were maintained at the rush Comparative research (CrC) 
animal facility, and all animal studies were approved by the 
rush University IaCUC committee.
tumor models
MCa205 (H12) is derived from 3-methylcholanthrene-
induced mice and can be passaged in culture. these cells 
were suspended in PBS and 0.3–1.0 × 106 injected s.c. 
into C57Bl/6 mice. the variant MCa205-OVa tumor cell 
line transgenically expresses the egg protein ovalbumin, 
as a surrogate antigen. eMt-6 tumor cells, derived from a 
mouse mammary carcinoma, were suspended in PBS and 
1 × 105 injected into the flanks of female Balb/c mice. 
Depending on the experiment, mice were then injected i.p. 
with 200–250 μg αOX40 (OX86) or rat Igg, 3 and 7 days 
following tumor challenge or 4, 6, and 10 days after tumor 
challenge. Mice were then monitored for tumor growth and 
killed if the tumor became ulcerated or growth reached 
150 mm2.
DO11.10, OtII, and OtI transgenic tCr adoptive transfer 
experiments
DO11.10 and OtII transgenic tCr CD4 t cells are specific 
to a peptide of the ovalbumin protein (a.a. 323–339) and can 
be identified by the antibody designated KJ-126 or the con-
genic marker thy1.1 or Vα2 and Vβ5. OtI transgenic tCr 
CD8 t cells, specific to a peptide of the ovalbumin protein 
(a.a. 257–264), were identified by the congenic marker 
thy1.1 or Vα2 and Vβ5. Spleens and lns were harvested 
and processed by crushing between two frosted glass micro-
scope slides and red blood cells lysed with aCK (lonza, 
Ca). the frequency and number of transgenic t cells 
were identified by FaCS analysis prior to transfer. a total 
of 1 × 106 transgenic tCr t cells were adoptively trans-
ferred i.v. into Balb/c or C57Bl/6 recipients. One day later, 
mice were immunized s.c. with 500 μg ovalbumin (Sigma, 
St. louis, MO) and 50 μg of OX40 agonist (OX86) or Igg 
control (Jackson Immunoresearch, Pa). the following day, 
mice were given a second injection of αOX40 or rat Igg. 
For experiments in the tumor setting, MCa205-OVa tumor 
cells (1 × 106) were transplanted 1 day after adoptive trans-
fer of 1 × 106 transgenic tCr OtII or OtI t cells. One 
day after tumor transplantation, mice were injected with 
200 μg of αOX40 or Igg control i.p. and a total of 7 days 
after tumor transplantation mice were killed.
FaCS analysis of t cells from antigen-draining lymph 
nodes
t cells were liberated from antigen-draining lns by dis-
ruption between two frosted glass slides and counted using 
a hemacytometer. Cells were stained with various combi-
nations of the following fluorescently labeled antibodies: 
PerCP Cy5.5.-CD4, aPC-CD25, Pe Cy7-CD8, Pe-CD25, 
aPC-KJ-126, FItC thy1.1, FItC Vβ5, aPC Vα2, e450-
CD62l, and biotinylated-KJ-126 (eBioscience, Ca). Har-
vested samples, isotype controls, and single stain controls 
were run on the FaCSCanto (Becton–Dickinson, nJ).
Intracellular cytokine staining
t cells from the antigen draining lymph nodes and con-
tralateral lymph nodes were harvested from DO11.10, 
OtII, or OtI adoptively transferred recipients 4 or 7 days 
after challenge and stimulated for at least 6 h in vitro with 
5 μg/ml ovalbumin323–339 (DO11.10 and OtII) or ovalbu-
min257–264 (OtI) and 1 μg/ml golgi stop (BD Biosciences 
Pharmingen, Ca). Cells were harvested and stained with 
PerCP Cy5.5-CD4, aPC-KJ-126, FItC thy1.1, FItC Vβ5, 
aPC Vα2, or aPC Cy7-CD8 (eBioscience, Ca). Cells 
were made permeable with CytoPerm/PermWash buffers 
and stained with Pe-Cy7-IFnγ (BD Biosciences Pharmin-
gen, Ca). t cells were analyzed on the BD FaCSCanto 
(Becton–Dickinson, nJ).
Statistical analysis
For all experiments, Student’s t test (two-tailed) was used to 
compare means of selected groups. For analysis, values of 
p ≤ 0.05 were considered significant and expressed as fol-
lows: *p ≤ 0.05 and **p ≤ 0.001 if not specifically stated.
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Results
Caloric restriction improves the ability of an 
OX40-targeted immune therapy to mediate tumor free 
survival in aged tumor-bearing mice
Our previous studies demonstrated the ability of αOX40 
treatment to be effective in improving tumor free survival 
in young tumor-bearing mice, but the same effect was 
not observed in older 12-month or 20-month-old tumor-
bearing mice [11]. Using the same MCa205 sarcoma 
tumor cell line, we sought to determine whether Cr would 
maintain effective αOX40-mediated anti-tumor immune 
responses in aged 12-month-old mice. Cr mice (mean age 
of 12 months) were purchased from the nIa. these mice 
were initially placed on a 40 % restricted diet (nIH31/nIa 
Fortified) at a young age (16 weeks) and maintained as 
outlined (www.nia.gov). Calorically restricted mice were 
weighed and compared to (1) 2-month-old mice, (2) 
12-month-old mice that were on an ad libitum laboratory 
rodent diet (al-lrD) (e.g., nIa31), and (3) mice that 
were on an al-lrD for 6 months followed by an ad libi-
tum purified diet (al-PD) until 12 months of age (Fig. 1a). 
the purified diet used, aIn93M, is comprised of less pro-
tein (12.4 vs 18.0 %) and fat (4.1 vs 4.7 %) when compared 
to a lrD, such as nIH31. Previous administration of the 
purified diet (al-PD) appeared to reduce the weight of the 
mice compared to normal rodent diet (al-lrD). the PD 
was initiated at 6 months of age, as this was a time when 
the αOX40-mediated anti-tumor immune response was 
intact and similar to the response in 2-month-old mice [11]. 
the weights of the aged dietary groups were significantly 
different, with the Cr group being the lightest and the al-
lrD being the heaviest (Fig. 1b). Prior to tumor challenge, 
the calorically restricted mice were placed on an ad libitum 
diet, as tumor growth could be slowed by calorie restriction 
alone. the aged mice were then injected s.c. on their right 
flanks with MCa205 tumor cells followed by i.p. injec-
tions of αOX40 or rat Igg 3 and 7 days later as previously 
described [11]. ad libitum (al-lrD and al-PD) mice and 
Cr mice treated with rat Igg failed to reject the tumors, 
and the tumors grew out rapidly (Fig. 1c, d, e). Interest-
ingly, in all experiments Igg control treated Cr mice expe-
rienced a significant increase in survival compared to ad 
libitum mice (Kaplan–Meier). Mice (12 months old) from 
both ad libitum groups (al-lrD and al-PD) treated with 
αOX40 had dramatically decreased tumor free survival 
when compared with the αOX40 treated caloric restricted 
(Cr) group of mice (Fig. 1c, d). 
In a second set of experiments, we extended our study 
of Cr on αOX40-mediated anti-tumor responses to include 
elderly mice. the mice aged 18 and 24 months of age (Cr 
and al-lrD) were challenged with MCa205 and treated 
with αOX40 and Igg controls like previously described. 
tumor survival of the αOX40-treated Cr mice was signifi-
cantly greater than control al-lrD tumor-bearing mice 18 
or 24 month of age (Fig. 2). these findings indicate that 
long-term Cr can enhance αOX40-mediated anti-tumor 
responses in 12-, 18- and 24-month-old mice.
neither resveratrol nor pterostilbene were able 
to significantly boost αOX40-mediated tumor immunity 
in aged tumor-bearing mice
the major drawback with Cr interventions for the broad 
prevention of human diseases is the difficulty of initiating 
and sustaining the 30–60 % restriction of caloric intake 
needed for beneficial effects. an alternative to Cr may 
reside in compounds that mimic Cr, such as resveratrol 
(reS). Unfortunately, the effects of reS on immunity 
are complex, conflicting, and largely untested in regard to 
aging and tumor immunity [23–26]. thus, to determine 
whether reS maintains beneficial tumor immunity, mice 
were fed a diet supplemented with reS. a commonly used 
purified diet was supplemented with reS (100 ppm) to 
produce an estimated daily dose of 12.5 mg/kg for a normal 
mouse. this dose is based on a report that showed long-
term ingestion of reS at this dose was well tolerated and 
closely mimicked the effects of Cr on biological system 
maintenance in mice [27]. Interestingly, reS, at doses 
ranging as low as 100 ng/kg and as high as 1,500 mg/kg, 
can also induce biological effects [19, 20]. the formu-
lated resveratrol diet (PD-reS) or the unsupplemented PD 
was introduced when mice were six months old and con-
cluded when they reached 12 months of age (Fig. 3a). at 
this time, the mice were weighed (Fig. 3b, d) and placed 
on the lrD, as reS has been shown to alter tumor growth 
[28]. the 12-month-old mice (PD-reS and PD) were chal-
lenged s.c. with MCa205 tumor cells treated with αOX40 
or rat Igg 3 and 7 days after tumor injection and tumor size 
measured (Fig. 3c). Dietary supplementation with reS 
failed to improve the αOX40-mediated anti-tumor immune 
responses in 12-month-old mice compared to control ani-
mals (PD). In addition, we assessed Balb/c mice placed on 
the same PD-reS and PD diets and challenged with the 
Fig. 1  agonist OX40-mediated tumor free survival was greater in 
calorically restricted 12-month-old mice compared to ad libitum con-
trols. a Dietary protocol; b 12-month-old female C57Bl/6 mice on a 
caloric restricted diet (Cr), an ad libitum laboratory rodent diet (al-
lrD) or an al-PD were weighed 1 day prior to tumor challenge and 
compared to 2-month-old mice; c 12-month-old al-lrD mice; or 
d 12-month of al-PD mice and 12-month-old (Cr) were injected 
s.c. with 3 × 105 MCa205 tumor cells. three and seven days later, 
αOX40 or rat Igg (200 μg) was injected i.p. and mice were assessed 
for survival (Kaplan–Meier). Data represent one of two independ-
ent experiments with n = 4–13 mice per treatment group; e tumor 
growth of individual mice
▸
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immunogenic tumor cell line eMt6. the αOX40 treatment 
induced significant tumor free survival in 2-month-old mice 
compared to rat Igg controls. However, there was no dif-
ference in tumor-free survival and tumor growth between 
12-month-old resveratrol (PD-reS) fed mice and control 
diet (PD) fed mice, with both 12-month-old groups expe-
riencing a dramatic decrease in survival compared to the 
αOX40-treated 2-month-old mice (Fig. 3e, f). these results 
indicate that dietary reS intake is unable to maintain effec-
tive anti-tumor immune responses in the context of αOX40 
treatment. 
In addition, the compound pterostilbene, a derivative 
of reS, has also been shown to reduce the affect of aging 
[29, 30] and has higher biological activity and greater bio-
availability than reS [31] was also tested. this compound 
represents another dietary supplement, similar to reS, with 
the potential to positively affect tumor immune responses 
during aging. Purified diet was supplemented with pter-
ostilbene (100 ppm), which correlated to the dose of reS 
previously used. the formulated pterostilbene diet (PD–
Pt) or the PD was introduced when mice were six months 
old and concluded when they reached 12 months of age. 
at 12 months, the mice on the pterostilbene diet were 
then placed on the PD, and all mice were challenged with 
eMt6 tumor and treated with αOX40 as described above. 
We observed no significant difference in OX40-mediated 
tumor-free survival between the pterostilbene fed mice and 
controls (Supplemental Figure 1).
Caloric restriction maintains antigen-specific CD4 t 
cell priming and activation in both the tumor setting 
and following protein immunization in aged mice
Both t cells and immune cells of the priming environment 
have been shown to be affected during aging; however, 
age-related deficiencies in the priming environment appear 
to significantly contribute to immune dysfunction [32, 
33]. Our previous findings demonstrate that young t cells 
undergo impaired t cell activation when primed in an older 
host and interestingly older t cells primed in a young host 
were not affected [11]. Furthermore, antigen-specific tumor 
immunity was significantly reduced in aged tumor-bearing 
mice, likely due to defects in the aged priming environ-
ment (Supplemental Figure 2). In these experiments, 2- and 
12-month-old mice received ovalbumin-specific CD4 t 
cells (2 or 12 months old) and were then challenged with 
a tumor cell line that expressed the surrogate antigen OVa. 
growth of this tumor, even though it expresses ovalbumin, 
is not significantly affected by αOX40 treatment in the 
absence of adoptively transferred t cells (data not shown). 
However, in adoptively transferred 2-month-old mice, the 
tumors experienced a significant decrease in size follow-
ing αOX40 treatment, regardless of the age of transferred t 
cells. In contrast, the tumors in all the older mice steadily 
increased in size (Supplemental Figure 2). thus, age-related 
deficiencies within the host environment could be the pri-
mary driver of impaired αOX40-mediated tumor regression.
A 18 months old B 24 months old








































Fig. 2  agonist OX40-mediated tumor survival was greater in calori-
cally restricted elderly mice compared to ad libitum controls. a 18- or 
b 24-month-old female C57Bl/6 mice on a caloric restricted diet (Cr) 
or an ad libitum laboratory rodent diet (al-lrD) were challenged 
(s.c.) with 3 × 105 MCa205 tumor cells. three and seven days later, 
αOX40 or rat Igg (200 μg) was injected i.p. and mice were assessed 
for survival (Kaplan–Meier). Data represent two independent experi-
ments with n = 6–9 mice per treatment group
621Cancer Immunol Immunother (2014) 63:615–626 
1 3
We sought to determine whether Cr would maintain the 
ability of the host priming environment to activate tumor 
antigen-specific t cells during aging. the priming and 
activation of both CD4 and CD8 t cells have shown to be 
required for effective OX40-mediated tumor immunity, as 
depletion of these cells abrogated the regression of tumors 
[34]; therefore, we assessed both antigen-specific CD4 and 
CD8 t cells. to avoid potential t cell intrinsic age-related 
deficiencies, young (2-month-old) ovalbumin-specific 
transgenic tCr CD4 t cells (OtII) or CD8 t cells (OtI) 
Fig. 3  long-term dietary sup-
plementation with resveratrol 
did not significantly increase 
αOX40-mediated tumor free 
survival in aged mice. a Dietary 
protocol; b 12-month-old 
female C57Bl/6 mice on a 
purified diet (PD) or a purified 
diet supplemented with 1 mg/
kg resveratrol (PD-reS) 
were weighed 1 day prior to 
tumor challenge; c resveratrol 
(PD-reS) and purified diet 
(PD) fed mice (12 months old) 
were injected s.c. with 3 × 105 
MCa205 tumor cells. three 
and seven days later, 200 μg 
αOX40 or rat Igg was injected 
(i.p.) and mice were monitored 
for tumor growth. Data are 
represented as a mean (±SeM) 
of one experiment (n = 10 per 
treatment group); d 12-month-
old female Balb/c mice on a 
purified diet (PD) or a purified 
diet supplemented with 1 mg/
kg resveratrol (PD-reS) were 
weighed 1 day prior to tumor 
challenge. resveratrol and puri-
fied diet fed mice (12 months 
old) were injected s.c. with 
1 × 105 eMt6 tumor cells. 
three and seven days later 
200 μg αOX40 or rat Igg were 
injected i.p. and mice were 
monitored for tumor growth; (e) 
and survival (Kaplan–Meier); 
(f). Quantitative date are 
represented as means (±SeM) 
from one of three independent 
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were adoptively transferred to young 2-month-old mice 
(2MO) or 12-month-old ad libitum mice (al-lrD) or Cr 
mice (Cr). the mice were then challenged s.c. with oval-
bumin-expressing MCa205 tumors. One day after, tumor 
challenge mice were injected with αOX40 or rat Igg and 
the draining lns harvested 7 days later (Fig. 4a). the num-
ber of cells found in the draining lns was not significantly 
different between the dietary groups (data not shown). 
total numbers of transgenic t cells were enumerated and 
the number of activated antigen-specific t cells, CD25+ 
and CD62llow, were calculated. the number of activated 
OtII t cells was higher in Cr mice compared to ad libitum 
mice (al-lrD) and similar to those seen in the reference 
2-month-old mice (2MO), reflecting an increase in the fre-
quency of this population (Fig. 4b). In contrast, the number 
of antigen-activated OtI CD8 t cells from Cr mice was 
similar to ad libitum mice (al-lrD) and significantly less 
than young mice (2MO) (Fig. 4c). these data suggest Cr 
maintains tumor-antigen-specific CD4 t cell priming to 
levels similar to young mice, but not CD8 t cell priming in 
the context of αOX40 treatment.
to verify our previous findings, we assessed the affect 
of Cr on the priming environment in an antigen-specific t 
cell model following s.c. immunization with protein anti-
gen. Young (2-month old) ovalbumin-specific OtII CD4 
t cells were adoptively transferred to young 2-month-old 
mice (2MO) as a reference or 12-month-old ad libitum 
(al-lrD) or Cr mice. adoptively transferred mice were 
then challenged with whole ovalbumin protein and αOX40 
or rat Igg. Four days after challenge, the draining lns were 
Fig. 4  Caloric restriction 
maintained priming of tumor 
antigen-specific CD4 t cells. 
a Schematic of experimental 
design. Specifically, 2-month-
old (2MO), 12-month-old 
al-lrD and Cr mice were 
adoptively transferred with 
1 × 106 OtII CD4 or 1 × 106 
OtI CD8 transgenic tCr t 
cells from a 2-month-old donor 
i.v. One day later, mice were 
transplanted s.c. with 1 × 106 
ovalbumin-expressing MCa205 
tumor cells (MCa205-OVa). 
One day after tumor transplan-
tation, mice were injected i.p. 
with 200 μg αOX40 or rat Igg. 
a total of 7 days after tumor 
transplantation, the tumor-
draining ln (tdln) was har-
vested, b numbers of total and 
activated OtII CD4 cells were 
determined by FaCs analysis of 
CD25 and CD62l expression, c 
numbers of total and activated 
OtI CD8 cells were determined 
by FaCs analysis of CD25 and 
CD62l expression. Quantitative 
date are represented as means 
(±SeM) from one of two inde-
pendent experiments (n = 3–5 
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harvested and the t cells assessed for activation and effec-
tor function. the number of activated (CD25+ CD62llow) 
and IFnγ-producing OtII CD4 t cells was significantly 
greater in the 12-month-old Cr mice than 12-month-old ad 
libitum mice (al-lrD) and was comparable with young 
2-month-old mice (2MO) (Fig. 5), verifying the findings 
from the tumor setting. thus, a second related antigen-
specific t cell model adds additional evidence that Cr 
maintains antigen-specific CD4 priming in the context of 
αOX40 treatment. 
Finally, the failure of reS to enhance αOX40-mediated 
tumor free survival in aged mice compared to aged con-
trol mice could be due in part to the inability of reS to 
maintain effective CD4 t cell priming. to test this, young 
(2 months old) ovalbumin-specific DO11.10 CD4 t cells 
were adoptively transferred to young 2-month-old mice or 
12-month-old control diet fed mice (PD) or 12-month-old 
PD-reS mice. the mice were then challenged with ovalbu-
min protein and αOX40 or rat Igg, as previously described. 
Four days later, the number and frequency of activated 
(CD25+ CD62llow) and IFnγ-producing DO11.10 CD4 
t cells in the draining lns were assessed. the absolute 
numbers of DO11.10 t cells from the antigen-draining 
lns of the αOX40-treated PD-reS mice were not signifi-
cantly different from those harvested from the PD control 
mice also treated with αOX40 (Fig. 6). However, the num-
bers of activate (CD25+ CD62llow) and IFnγ+ cells were 
significantly greater in the aged αOX40-treated reS mice 
and control PD mice, but remained dramatically less than 
levels observed in the reference 2MO αOX40-treated mice 
(Fig. 6).
Discussion
Our results demonstrate the ability of caloric restriction 
(Cr) to support immune responses against tumors and effec-
tively maintain CD4 t cell priming during aging. long-term 
Cr has previously been established to enhance immunity 
against certain pathogens during aging [35] and the data pre-
sented here extend Cr-mediated immune enhancement to 
include increasing tumor immune responses mediated by an 
immunotherapy. In contrast, a second dietary intervention 
considered to mimic Cr, resveratrol (reS) failed to signifi-
cantly affect these tumor immune responses following long-

























































































































Fig. 5  antigen-specific t cell responses were maintained in calori-
cally restricted aged mice. 2-month-old, 12-month-old al-lrD 
and 12-month-old Cr female C57Bl/6 mice were injected i.v. with 
1 × 106 OtII CD4 t cells t cells from 2-month-old donors. One day 
later, mice were injected s.c. with 500 μg ovalbumin and 50 μg of 
αOX40 or rat Igg. Four days after antigen challenge, the draining 
lns were harvested and the antigen-specific t cells were enumerated. 
OtII cells were assessed for the expression of the activation markers 
CD25 and CD62l and the production of IFnγ after overnight restim-
ulation with OVa peptide (a.a. 323–339). Quantitative date are repre-
sented as means (±SeM) from one of three independent experiments 
(n = 3–5 mice per treatment group)
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was observed to maintain priming and activation of antigen-
specific CD4 t cells, at levels comparable to young reference 
animals in the context of αOX40. It is well understood that 
adaptive t cell-mediated immune responses are critical for 
effective and durable tumor rejection. Our results suggest the 
effect of Cr on enhancing anti-tumor responses in aged hosts 
appears to be due in part to the maintenance of the priming 
environment during aging, which facilitates CD4 t cell acti-
vation in the aged hosts following immune stimulation.
It was surprising that the expansion of antigen-activated 
CD8 t cells primed in aged Cr mice was not significantly 
different from cells primed in ad libitum controls, yet aged 
Cr mice exhibited substantial tumor clearance following 
αOX40 treatment. CD8 t cells are considered the primary 
mediators of tumor destruction and are the focus of a num-
ber of immune therapies. In addition, CD8 responses have 
been shown to be responsive to OX40 stimulation [36, 37] 
and both CD4 and CD8 t cells are needed for αOX40-
mediated tumor immunity [34]. the disparity in antigen-
specific t cell priming (CD4 > CD8) in Cr mice suggests 
Cr maintains the function of a specific subset of antigen 
presenting cells that prime CD4 t cells. Various DC sub-
sets have been shown to have differential t cell priming 
capacities. For instance, lymphoid resident CD8+ DCs 
are considered the primary activators of CD8 t cells, via 
cross-presentation [38], and DCs that migrate from the skin 
have shown a preference to activate CD4 t cells [39]. this 
migratory DC subset and other DC subsets, like inflamma-
tory monocyte derived DCs [40], are potent producers of 
Il-12, a critical cytokine for the activation of CD4 t cells. 
Il-12 plays a key role in the activation of th1 CD4 t cells, 
and we have previously demonstrated that the addition of 
exogenous Il-12 can partially restore CD4 t cell responses 
and tumor immunity in aged tumor-bearing animal [11]. 
thus, it is possible Il-12 producing DC subsets are sensi-
tive to the effects of aging and long-term Cr better main-
tains these DC subsets during aging.
It has been well documented that Cr can maintain an 
organism’s “health-span” and our data further expand this 
concept into tumor immunity and tumor immunotherapy. 
It is well established that animals subjected to long-term 
Cr developed fewer tumors than ad libitum fed animals 
[41]. an underlying reason for this phenomenon could be 
the maintenance of tumor immune responses. Our studies 
in aged mice show tumor immune responses induced by a 
potential immune therapy, αOX40, could be enhanced in 
aged animals following Cr. a previous study has demon-
strated that αOX40 can boost anti-tumor immune responses 
in aged mice [42], which is also shown in Fig. 3c (PD Igg 
and PD αOX40); however, Cr induces a more pronounced 
effect on tumor free survival in aged αOX40-treated tumor-
bearing mice. Other immunotherapies, such as antagonistic 
antibodies to the checkpoint inhibitor Ctla-4 and tumor 
vaccines, may also be enhanced by Cr in aged host. We 
have preliminary data that suggest that in mouse models, 
aging diminishes both the effect of Ctla-4 on the growth 
of B16 melanoma and the ability of an anthracyclin-based 
































































































Fig. 6  resveratrol dietary supplementation and antigen-specific 
CD4 t cell responses in aged hosts. Six-month-old female Balb/c 
mice were placed on a purified diet (PD) or a 1 mg/kg resveratrol 
diet (reS) for 6 months. at 12 months of age, mice were returned to 
normal rodent chow diets and 2-month-old DO11.10 cells (1 × 106) 
transferred into the aged mice and 2-month-old wt mice. One day 
later mice were injected s.c. with 500 μg ovalbumin and 50 μg of 
αOX40. Four days after ag challenge, draining lns were harvested 
and the antigen-specific t cells were enumerated and assessed for 
the expression of the activation markers CD25 and CD62l and the 
production of IFnγ after overnight restimulation with OVa peptide 
(CD4 a.a. 323–339). Quantitative date are represented as means 
(±SeM) from one of two independent experiments (n = 4 mice per 
treatment group)
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(data not shown). Cr could maintain tumor immunity to 
boost the effectiveness of these two types of immunothera-
pies in mice and potentially humans. Interestingly, it appears 
that endogenous anti-tumor immune responses are also sup-
ported by Cr. Control 12-month-old Cr tumor-bearing 
animals (Igg treated animals) experienced a consistent 
and statistically significant increase in survival (Fig. 1c, d). 
looking at the endogenous anti-tumor responses in elderly 
mice, we failed to observe these effects in older 18-month-
old mice (Fig. 2), suggesting these responses wane with age 
regardless of the Cr dietary intervention.
Caloric restriction may affect several biological pro-
cesses besides the immune system that could account for 
the increased survival of the tumor-bearing mice. Body 
mass and fat, which have been shown to be related to spe-
cific types of tumor genesis and growth (e.g., breast and 
colon) [43], are reduced in Cr animals. the mass of the 
Cr animals and the ad libitum fed animals on lrD and PD 
was indeed highly significant (Fig. 1b). We also observed a 
significant difference in mass between ad libitum animals 
on different formulation of diet, lrD and PD. Yet there 
was no difference in the survival of the Igg treated mice 
between the two groups (data not shown). additional stud-
ies are needed to determine the contribution of body mass 
and fat on tumor immunity in this model.
Due to difficulties with maintaining Cr over the long 
term, Cr mimics like reS could be considered options 
for maintaining tumor immune protection during aging. 
In fact, reS has been identified as a candidate for cancer 
chemoprevention [44] and as a Cr mimetic that increases 
“healthspan” [45]; however, reS supplementation did not 
maintain anti-tumor immune function in the context of 
αOX40 treatment. reS had a minor effect on the activation 
of CD4 t cells, but it was four- to fivefold less than young 
reference mice (2MO) and more importantly had no sig-
nificant effect on tumor growth and clearance. In contrast, 
t cell responses in Cr mice were similar to young mice. 
a potential explanation for the discrepancy between reS 
and Cr could be the bioavailability of reS. greater than 
50 % of reS is bioavailable in rodents and humans shortly 
after ingestion, but reS then undergoes rapid metabo-
lism in the liver, as well as enterohepatic cycling where 
the metabolized reS is reabsorbed in the intestine further 
diminishing concentrations in the blood [46, 47]. levels of 
reS were not measured in these experiments, but as Bauer 
et al. showed the dose of reS administered in the diet can 
produce significant biological effects during aging. How-
ever, our findings may suggest that higher doses of reS 
are needed to sustain immune responses; thus, additional 
experiments are required to fully determine whether reS 
can maintain immunity during aging.
these findings have important theoretical implications 
for optimizing the effect of immune-based cancer therapies 
in elderly patients and for cancer prevention. Cr or pos-
sibly an effective mimic initiated when immune responses 
retain the capacity to regress tumors could preserve endog-
enous tumor immune surveillance and increase the effec-
tiveness of tumor immunotherapies, such as vaccines and 
an αOX40. In conclusion, our results show Cr maintains 
immune responses against tumors in aged mice following 
the stimulation of OX40, a likely target for tumor immuno-
therapy, and suggest the aged host environment is a critical 
contributor to immune deficiency during aging.
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